Methods for predicting drug sensitivity in patients afflicted with an inflammatory disease
Patent 7148008 Issued on December 12, 2006. Estimated Expiration Date: September 3, 2022. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
Methods are disclosed for predicting the efficacy of a drug for treating an inflammatory disease in a human patient, including: obtaining a sample of cells from the patient; obtaining a gene expression profile of the sample in the absence and presence of in vitro modulation of the cells with specific cytokines and/or mediators; and comparing the gene expression profile of the sample with a reference gene expression profile, wherein similarities between the sample expression profile and the reference expression profile predicts the efficacy of the drug for treating the inflammatory disease in the patient.
Other References
Villeneuve et al. Current Topics in Medicinal Chemistry, vol. 4, No. 13, pp. 1453-1458, 2004 (Abstract only).
Arend, W., “Physiology of Cytokine Pathways in Rheumatoid Arthritis,” Arthritis Care and Research 45:101-106 (2001).
Barnes, P. et al., “Efficacy and Safety of Inhaled Corticosteroids,” Am. J. Respir. Crit. Care. Med. 157:S1-S53 (1998).
Broide, D. et al., “Cytokines in Symptomatic Asthma Airways,” J. Allergy Clin. Immunol. 89:958-967 (1992).
Eggleston, P. and Bush, R., “Environmental allergen avoidance: An Overview,” J. Allergy Clin. Immunol. 107:S403-5 (2001).
“Genes for Asthma? An Analysis of The European Community Respiratory Health Survey,” Am. J. Respir. Crit. Care Med. 156:1773-1780 (1997).
Golub, T., et al., “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring,” Science 286: 531-537 (1999).
Gulcher, J. and Stefansson, K., “Population Genomics: Laying the Groundwork for Genetic Disease Modeling and Targeting,” Clin. Chem. Lab. Med. 36: 523-527 (1998).
Grunstein M. et al. “Autocrine signaling by IL-10 mediates altered resonsiveness of atopic sensitized airway smooth muscle,” Am. J. Physiol. Lung Cell. Mol. Physiol. 281: L1130-7 (2001).
Hakonarson, H. et al. “Autocrine Role of Interleukin 1β in Altered Responsiveness of Atopic Asthmatic Sensitized Airway Smooth Muscle,” J. Clin. Invest. 99: 117-124 (1997).
Hakonarson, H. et al. “Mechanism of Rhinovirus-induced Changes in Airway Smooth Muscle Responsiveness,” J. Clin. Invest. 102: 1732-1741 (1998).
Hakonarson, H. et al. “Autocrine interation between Il-5 and IL-1β mediates altered responsiveness of atopic asthmatic sensitized airway smooth muscle,” J. Clin. Invest. 104: 657-667 (1999).
Hakonarson, H. et al. “Association between Il-lbeta/TNF-alpha Induced Glucocorticoid-Sensitive Changes in Multiple Gene Expression and Altered Responsiveness in Airway Smooth Muscle,” Am. J. Respir. Cell Mol. Biol. 25: 761-71 (2001).
Leung, D. and Chrousos, G., “Is There a Role for Glucocorticoid Receptor Beta in Glucocorticoid-dependent Asthmatics,” Am. J. Respir. Crit. Care Med. 162: 1-3 (2000).
Keller, A., et al., “Bayesian classification of DNA array expression data,” Technical report, Department of Computer Science and Engineering, University of Washington (Aug. 2000).
Heller, Renu A. et al., “Discovery and Analysis of Inflammatory Disease-Related Genes Using cDNA Microarrays,” Proc. Natl. Acad. Sci. USA, 94:2150-2155 (1997).
Clarke, P., et al., “Gene Expression Profiling of Human Colon Cancer Cells Following Inhibition of Signal Transduction by 17-Allylamino-17-Demethoxygeldanamycin, an Inhibitor of the hsp90 Molecular Chaperone,” Oncogene, 19:4125-4133 (2000).
Galon, J., et al., “Gene Profiling Reveals Unknown Enhancing and Suppressive Actions of Glucocorticoids on Immune Cells,” FASEB Journal, 16:61-71 (2002).
Heyninck, K., et al., “The Cytokine-Inducible Zinc Finger Protein A20 Inhibits IL-1 Induced NF-κB Activation at the Level of TRAF6,” FEBS, 442:147-150 (1999).
Khoo, C., et al., “Differential Expression of Cysteine-rich Intestinal Protein in Liver and Intestine in CC14-Induced Inflammation,” American Physiological Society, 270:G613-G618 (1996).
Saban, M., et al., “Time Course of LPS-Induced Gene Expression in a Mouse Model of Genitourinary Inflammation,” Physiol. Genomics, 5:147-160 (2001).
Sutherland, A., “Gene Expression Analysis in Immunmodulatory and Inflammatory Model Systems Using Affymetrix Genechip Expression Arrays,” Cell Biology International, 24:975 (2000), abstract.
Ahmed, S., et al., “Novel Polymorphism in the Coding Region of the IL-13 Receptor Alpha' Gene: Association Study with Atopic Asthma in the Japanese Population,” Exp. Clin. Immunogenet. 17:18-22 (2000).
Asher, B., J. Mol. Graph Model., 18:79-82 (2000).
Gagliardo, R. et al., “Glucocorticoid Receptor α and β in Glucocorticoid Dependent Asthma,” Am. J. Respir. Crit. Care Med., 162:7-13 (2000).
“Guidelines for the Diagnosis and Management of Asthma”: Expert Panel Report 2, Jul. 1997, National Institutes of Health, NIH Publication No. 97-4051 (1997). U.S. Government Printing Office, Washington, D.C.
Heinzmann, A. et al., “Genetic variants of IL-13 signalling and human asthma and atopy,” Hum. Mol. Genet., 9:549-59 (2000).
Kauppi, P. et al., “The IL9R region contribution in asthma is supported by genetic association in an isolated population,” Eur. J. Hum. Genet., 8:788-92 (2000).
“Standardization of Spirometry”, American Thoracic Society, (1994 update), Am. J. Respir. Crit. Care. Med., 152:1107-1136 (1995).
Malnistrom, et al., “Oral Montelukast, Inhaled Beclomethasone, and Placebo for Chronic Asthma,” Annals Internal Medicine, vol. 130, pp. 487-495 (1999).
September 3, 2022. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
